RESEARCHER PROFILE
Kazım Uygun
← Back to Kocaeli Üniversitesi
K
Kocaeli Üniversitesi
Kazım Uygun works in Breast Cancer Treatment Studies, Gastric Cancer Management and Outcomes, Metastasis and carcinoma case studies, Lung Cancer Diagnosis and Treatment, Head and Neck Cancer Studies. Recorded institutional associations include Kocaeli Üniversitesi.
202Publications
1,786Citations
18H-index
Inclusion identifies researchers whose recorded research contributions may inform their university’s understanding of its research community. It does not rank individual research quality or establish current employment.
Selected research works
Up to 100 highly cited works; DOI links open the original research. Counts reflect the collected record, not real-time citation totals.
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer
2021 · 734 citationsMultiple Primary Neoplasms at a Single Institution
2000 · 113 citationsExtrapulmonary small‐cell carcinoma compared with small‐cell lung carcinoma
2007 · 103 citationsGranulosa Cell Tumor of the Ovary
2003 · 79 citationsClinical parameters and treatment results in recurrent granulosa cell tumor of the ovary
2003 · 54 citationsThe comparison of weekly and three-weekly cisplatin chemotherapy concurrent with radiotherapy in patients with previously untreated inoperable non-metastatic squamous cell carcinoma of the head and neck
2009 · 52 citationsNetrin-1 in cancer: Potential biomarker and therapeutic target?
2017 · 49 citationsSafety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study's primary analysis of 2573 patients
2017 · 46 citationsColonic Metastasis from Carcinoma of the Breast that Mimicks a Primary Intestinal Cancer
2006 · 45 citationsEpidemiology of colorectal cancer in Turkey: A cross-sectional disease registry study (A Turkish Oncology Group trial)
2015 · 34 citationsEffect of maximum-tolerated doses and low-dose metronomic chemotherapy on serum vascular endothelial growth factor and thrombospondin-1 levels in patients with advanced nonsmall cell lung cancer
2007 · 31 citationsThe efficacy of tamoxifen in patients with advanced epithelial ovarian cancer
2007 · 29 citationsDo High-risk Features Support the Use of Adjuvant Chemotherapy in Stage II Colon Cancer? A Turkish Oncology Group Study
2014 · 26 citationsPrognostic role of neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, systemic immune-inflammation index, and pan-immune-inflammation value in metastatic castration-resistant prostate cancer patients who underwent 177Lu–PSMA-617
2023 · 25 citationsTP53, EGFR and PIK3CA gene variations observed as prominent biomarkers in breast and lung cancer by plasma cell-free DNA genomic testing
2019 · 22 citationsEvaluation of Cardiotoxicity via Speckle-Tracking Echocardiography in Patients Treated with Anthracyclines
2013 · 21 citationsIsolated bilateral sixth nerve palsy secondary to metastatic carcinoma: a case report with a review of the literature
2003 · 20 citationsThe Effect of Tumor Size on Overall Survival in Patients with pT3 Gastric Cancer: Experiences from 3 Centers
2010 · 19 citationsAdjuvant Intraperitoneal Chemotherapy With Cisplatinum, Mitoxantrone, 5-Fluorouracil, and Calcium Folinate in Patients With Gastric Cancer
2002 · 18 citationsIsolated Bone Metastasis in Testicular Germ Cell Tumors: A Case Report and Review of the Literature
2006 · 17 citationsNasopharyngeal Carcinoma with Extensive Nodular Skin Metastases: A Case Report
2006 · 17 citationsThe Roles of Chemotherapy and Surgery in Gastric Carcinoma and the Influence of Prognostic Factors on Survival
2000 · 16 citationsPrimary Synovial Sarcoma of Lung
2014 · 15 citationsPrognostic factors in elderly patients with non-small cell lung cancer: a two-center experience
2010 · 15 citationsXeliri Plus Bevacizumab Compared with Folfiri Plus Bevacizumab as First-Line Setting in Patients with Metastatic Colorectal Cancer: Experiences at Two-Institutions
2013 · 13 citations
